Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 1/20 | 0.56 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23631701 | 0.90 | KRAS (0.46) | KRASKMT2AALDH1A1HTTAR | |
| SCHEMBL23631580 | 0.88 | NTSR1 (0.51) | KRASNTSR1 | |
| SCHEMBL3184801 | 0.86 | KRAS (0.55) | KRASPLGPLAUSLC6A2KMT2A | |
| SCHEMBL23631591 | 0.81 | NTSR1 (0.43) | KRASKMT2AALDH1A1HTTNTSR1 | |
| SCHEMBL23631648 | 0.80 | NTSR1 (0.60) | KRASKMT2AALDH1A1HTTNTSR1 | |
| SCHEMBL13299389 | 0.79 | KRAS (0.54) | KRASPLGPLAUSLC6A2AR | |
| SCHEMBL14876295 | 0.79 | ATM (0.55) | KRASPLGPLAUSLC6A2KMT2A | |
| SCHEMBL23631640 | 0.78 | KDM4E (0.51) | KRASKMT2AALDH1A1HTTAR | |
| SCHEMBL5591112 | 0.78 | KRAS (0.52) | KRASPLGPLAUSLC6A2AR | |
| SCHEMBL6138108 | 0.76 | KMT2A (0.69) | KMT2AALDH1A1HTTNTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214359-A1 | Compounds and Methods for Treating Bacterial Infections | UNIV NEW YORK (US) | 2021-07-15 | — | — | US | claimed |
| US-20210214359-A1 | Compounds and Methods for Treating Bacterial Infections | UNIV NEW YORK (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210214359-A1 | Compounds and Methods for Treating Bacterial Infections | UNIV NEW YORK (US) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214359-A1 | Compounds and Methods for Treating Bacterial Infections | CBS, MPO, QSOX1 | KRAS 1973/4885PLG 582/4885PLAU 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.